Macdonald F, Crowson M C, Allum W H, Life P, Fielding J W
Cancer Immunol Immunother. 1986;23(2):119-24. doi: 10.1007/BF00199817.
A number of criteria have been investigated to try to improve the uptake of radiolabelled antibodies by colorectal carcinoma xenografts. The in vivo behaviour of four antibodies was compared and found to vary. Two antibodies, 11-285-14 and 14-95-55, demonstrated specific uptake by the tumours. 11-357-5 was lost from the tumour after 72 h and the fourth antibody could not be iodinated without loss of activity. Neither increased time nor increased dose were shown to increase the uptake of antibody by tumours although the clearance of antibody from blood was shown to be more rapid than from tumour resulting in clearer backgrounds. Increased tumour:blood ratios were demonstrated by particular combinations of antibodies but the extent to which this occurred varied with the epitopes recognised. High carcinoembryonic antigen expressing xenografts did not show significantly higher uptake of antibody. This was shown to be due to the smaller size of these tumours and associated decreased vascularity.
为了提高放射性标记抗体在结直肠癌异种移植瘤中的摄取，人们研究了许多标准。比较了四种抗体的体内行为，发现它们有所不同。两种抗体，11 - 285 - 14和14 - 95 - 55，显示出肿瘤对其有特异性摄取。11 - 357 - 5在72小时后从肿瘤中消失，第四种抗体在不丧失活性的情况下无法碘化。尽管抗体从血液中的清除比从肿瘤中更快，从而使背景更清晰，但延长时间和增加剂量均未显示能增加肿瘤对抗体的摄取。特定的抗体组合显示肿瘤与血液的比例增加，但这种增加的程度因所识别的表位而异。高癌胚抗原表达的异种移植瘤并未显示出抗体摄取明显更高。结果表明，这是由于这些肿瘤体积较小且血管分布减少所致。
